Back to Search
Start Over
Cancer Immunotherapy for the General Surgeon.
- Source :
-
The American surgeon [Am Surg] 2020 Apr 01; Vol. 86 (4), pp. 284-292. - Publication Year :
- 2020
-
Abstract
- Progress in the arena of cancer immunotherapy has been immense in recent years. The fact remains that most of the cancer resections in the United States are performed by general surgeons and not oncologic specialists. A busy practice in general surgery will invariably make it difficult to keep pace with such rapid advancement. This review offers a concise summary of the major concepts and trials that have driven the immunotherapy revolution and their implications for surgeons who deliver cancer care.
- Subjects :
- CTLA-4 Antigen antagonists & inhibitors
CTLA-4 Antigen immunology
Carcinoma, Hepatocellular drug therapy
Carcinoma, Non-Small-Cell Lung drug therapy
Chemotherapy, Adjuvant
Gastrointestinal Neoplasms drug therapy
Humans
Liver Neoplasms drug therapy
Programmed Cell Death 1 Receptor immunology
Immunotherapy adverse effects
Melanoma drug therapy
Programmed Cell Death 1 Receptor antagonists & inhibitors
Skin Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1555-9823
- Volume :
- 86
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- The American surgeon
- Publication Type :
- Academic Journal
- Accession number :
- 32391751